Cargando…

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score

BACKGROUND: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT scans. We aimed to validate previous single-centre findings in a mult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, David L., Hayes, Aimee R., Karfis, Ioannis, Conner, Alice, Furtado O’Mahony, Luke, Mileva, Magdalena, Bernard, Elizabeth, Roach, Paul, Marin, Gwennaëlle, Pavlakis, Nick, Schembri, Geoffrey, Gnanasegaran, Gopinath, Marin, Clementine, Vanderlinden, Bruno, Navalkissoor, Shaunak, Caplin, Martyn E., Flamen, Patrick, Toumpanakis, Christos, Bailey, Dale L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938218/ https://www.ncbi.nlm.nih.gov/pubmed/36434154 http://dx.doi.org/10.1038/s41416-022-02061-5

Ejemplares similares

Accuracy and precision assessment for activity quantification in individualized dosimetry of (177)Lu-DOTATATE therapy
por: Marin, Gwennaëlle, et al.
Publicado: (2017)

Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms
por: Laskaratos, Faidon-Marios, et al.
Publicado: (2019)

Prognostic value of a three-scale grading system based on combining molecular imaging with (68)Ga-DOTATATE and (18)F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
por: Karfis, Ioannis, et al.
Publicado: (2020)

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE
por: Delbart, Wendy, et al.
Publicado: (2023)

Understanding the Radiobiological Mechanisms Induced by (177)Lu-DOTATATE in Comparison to External Beam Radiation Therapy
por: Delbart, Wendy, et al.
Publicado: (2022)

Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case report
por: Manta, Ringo, et al.
Publicado: (2022)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
por: Mileva, Magdalena, et al.
Publicado: (2020)

Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
por: Manoharan, Prakash, et al.
Publicado: (2020)

Insulinoma: a quarter century of dietary control
por: Boharoon, Hessa, et al.
Publicado: (2022)

(90)Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer
por: Levillain, Hugo, et al.
Publicado: (2018)

Efficacy and safety of (177)Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study
por: Clement, Dominique, et al.
Publicado: (2022)

Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
por: Komek, Halil, et al.
Publicado: (2019)

The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
por: Hindié, Elif
Publicado: (2017)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Gallium-68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience
por: Aslani, Alireza, et al.
Publicado: (2014)

Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Koffas, Apostolos, et al.
Publicado: (2023)

Clinical and Prognostic Value of PET/CT Imaging with Combination of (68)Ga-DOTATATE and (18)F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Zhang, Panpan, et al.
Publicado: (2018)

Case Report of Tc-99m Sulfur Colloid Single-Photon Emission Computed Tomography/Computed Tomography Study Differentiating Tumor from Accessory Spleen
por: Aggarwal, Reena, et al.
Publicado: (2013)

Lutetium oxodotreotide ((177)Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
por: Smith-Palmer, J., et al.
Publicado: (2021)

Quantitative (177)Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera
por: Danieli, Rachele, et al.
Publicado: (2023)

Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study
por: Mandair, Dalvinder, et al.
Publicado: (2022)

Is there a Role for Gallium-67 Citrate SPECT/CT, in Patients with Renal Impairment or Who are Renal Transplant Recipients, in Identifying and Localizing Suspected Infection?
por: Nowosinska, Ewa, et al.
Publicado: (2015)

Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
por: Diamantopoulos, Leonidas N., et al.
Publicado: (2023)

Use of [(177)Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
por: Glover, Matthew, et al.
Publicado: (2021)

Optimizing the Schedule of PARP Inhibitors in Combination with (177)Lu-DOTATATE: A Dosimetry Rationale
por: Hallqvist, Andreas, et al.
Publicado: (2021)

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
por: Ramage, John K, et al.
Publicado: (2011)

Long-Term Survival and Value of (18)F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with (177)Lu-DOTATATE
por: Rodrigues, Margarida, et al.
Publicado: (2021)

Personalized selective internal radiation therapy in liver metastasis of thyroid cancer with impaired liver function: A case report
por: Herchuelz, Maxime, et al.
Publicado: (2020)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

Clinical features of gastroenteropancreatic tumours
por: Gut, Paweł, et al.
Publicado: (2015)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

(177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience
por: Satapathy, Swayamjeet, et al.
Publicado: (2021)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Mafficini, Andrea, et al.
Publicado: (2019)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma
por: Mollazadegan, Kazhan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cr6eofkcvnntb27a64r82ipibd